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mortality than patients without chronic anticoagulation.
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Background: Changes in ST-segment deviation and heart rate (HR), continuously
monitored with a permanently implanted RV apical pacemaker lead and monitor,
provide unique information for coronary disease patients. We report on the first patients
from centers in the US and Brazil. Monitors provide two real-time alarms: an
“EMERGENCY” alarm (EA) for STEMI, triggered by primary ST deviation, and a
“SEE DOCTOR” (SD) alarm, triggered by HR related ST deviation. We report major
adverse cardiac event (MACE) rates and present case studies for each alarm type.
Methods: Monitors were implanted in 76 CAD patients with high-risk TIMI scores.
EAs occurred when ST-segments changes exceeded individualized baseline (BL) ST
thresholds prior to HR change. Three SDs were configured: SD1. ST-segment changes,
following elevated HRs, exceeded BL ST-Thresholds; SD2. elevated-HR for at least
10 minutes with ST-changes; or, SD3. a trend of daily ST-deviation values exceeded
an alarm criterion. Data were retrieved at both periodic check-up and alarm prompted
visits.
Results: During a follow-up period of 181.4 patient-years (median=2.2 yr, range 3
mnth-5 yr) ST-segment related EAs and SDs occurred in 23 (30%) and 26 (34%)
patients, respectively. The SD1, SD2, and SD3 alarms occurred 12, 26, and 11 times,
respectively. There was a MACE rate of 33%: 4 STEMIs, 15 NSTEMIs, and 6 deaths.
There were 25 revascularizations.
Conclusion: Continuous intracardiac monitoring in high-risk ACS patients provides
unique clinical information. We report clinical events from the first human experience
using such devices with real time alarm capabilities. Primary ischemia documented as
EAs is more likely to represent spontaneous plaque rupture with interruption of
coronary flow, while secondary ischemia related to HR elevation is likely to represent
demand-related ischemia with more stable plaque. Further study of the clinical value
of real-time ST-deviation detection systems will provide a new window of information
in high risk patients with CAD.
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Coronary Syndromes:An OCT study
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Background: Thrombus aspiration (TA) and local intracoronary delivery of abciximab
(LIDA) by means of a dedicated perfusion catheter have been shown to be feasible
and effective in reducing thrombus burden and improving myocardial reperfusion in
patients (pts) with STEMI and NSTEMI. Aim of the present study is to compare the
impact on thrombus burden reduction of TA or LIDA, as assessed by frequency-domain
OCT (FD-OCT), in pts with acute coronary syndrome (ACS).
Methods: Twenty consecutive patients with ACS, scheduled for coronary angioplasty
and LIDA were matched 1:1 with pts included in a previous registry of TA. FD-OCT
assessment of culprit/thrombotic lesion was performed at basal (PRE) and after device
passage (POST). Intracoronary thrombus was assessed using a validated score on the
basis of previously published studies.The following parameters were calculated: PRE
thrombus score, POST thrombus score, % thrombus removal (PRE minus POST / PRE
x 100). Quantitative coronary analysis: TIMI flow, corrected TIMI Frame Count (C-
TFC), myocardial blush grade (MBG) were calculated.
Results: The mean value of basal thrombus score was 105.4 + 48.6 in LIDA group
and 118.8 + 90.7 in TA group (p=0.29); after device passage, thrombus score decreased
to 68.5 + 45.2 in LIDA group and to 58.2 + 48.8 in TA group (p=0.26). The TA group,
compared to LIDA group, had significantly more amount of % thrombus removal: 51.3
+ 24.0 vs 32.5 + 30.1, p=0.03. After stent deployment, LIDA group, compared to TA
group, did not have significative difference in terms of final TIMI flow (2.9 + 0.3 vs
2.8 + 0.4; p=0.2), C-TFC (12.2 + 6.9 vs 13.4 + 4.2; p=0.2) and MBG (2.8 + 0.4 vs 2.6
+ 0.6; p=0.19)
Conclusion: TA had a more significant impact on the reduction of thrombus burden
than LIDA, nonetheless the effects on the microcirculatory function were similar. This
apparent discrepancy between the mechanical thrombus reduction and its
microcirculatory effects requires a targeted investigation.
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Background: To evaluate the independent prognostic value of qualitative and
quantitative admission electrocardiogram (ECG) analysis regarding long-term
outcomes after non-ST-elevation acute coronary syndrome (NSTE-ACS).
Methods: From the FRISC II – ICTUS – RITA-3 patient-pooled database, 5420 NSTE-
ACS patients with qualitative ECG data of which 2901 with quantitative data were
included in this analysis. The main outcome was 5-year cardiovascular death or
myocardial infarction (MI). Hazard ratios (HR) were calculated with Cox regression
models, adjustments were made for established outcome predictors. Interaction
between ECG characteristics and treatment strategy was assessed. Additional
discriminative value was assessed with the categoryless net reclassification
improvement (NRI) and integrated discrimination improvement (IDI).
Results: In the 5420 patients, the presence of ST-segment depression (≥1mm, adjusted
HR 1.43, 95%CI: 1.25–1.63) and left bundle branch block (LBBB) (adjusted HR 1.64,
95%CI: 1.18–2.28) were independently associated with long-term CV death or MI.
Risk increases were both short-term and long-term. Second, in quantitative ECG
analysis, cumulative ST-segment depression (≥5mm, adjusted HR 1.34, 95%CI: 1.05–
1.70), the presence of LBBB (adjusted HR 2.15, 95%CI: 1.36–3.40) or ≥6 leads with
an inverse T-wave (adjusted HR 1.22, 95%CI: 0.97–1.55) were independently
associated with long-term outcomes. No interaction was observed with treatment
strategy. No improvement in NRI and IDI were observed after addition of quantitative
characteristics to a model including qualitative characteristics.
Conclusion: In the FIR NSTE-ACS patient-pooled dataset, admission ECG
characteristics provide long-term prognostic value for CV death or MI. Quantitative
ECG characteristics provided no incremental discrimination compared with qualitative
data.
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Background: Troponin elevation is a risk factor for mortality in non ST-segment
elevation acute coronary syndromes (NSTEACS). The prognosis of ACS patients with
troponin elevation and non-obstructive coronary artery disease (CAD) is unknown.
Methods: Patients with moderate and high-risk NSTEACS with elevated baseline
troponin levels in the angiographic core laboratory substudy of the ACUITY trial were
stratified by the presence or absence of obstructive CAD (stenosis ≥50%).
Results: Of 2,442 pts with elevated troponins, 197 (8.8%) had non-obstructive CAD.
Maximal diameter stenosis was 83.5%±17.5 vs. 24.1%±12.2 (p<0.0001) in patients
with vs. without obstructive CAD. Patients with non-obstructive CAD were younger
(median age [IQR] =54 [45, 63] vs. 60 [52, 70], p<0.0001) and more frequently women
(53.3% vs. 32.0%, p<0.0001), and had lower TIMI risk score (TIMI 5-7: 10.8% vs.
28.8%, p<0.0001). The overall and cardiac mortality rates were not significantly
different than in pts with obstructive CAD, and those with non-obstructive CAD had
greater non-cardiac mortality (Table). Conversely, recurrent MI and unplanned
revascularization rates were significantly higher in pts with obstructive CAD. By
multivariable analysis, a trend was present toward increased 1-year mortality in pts
without compared to those with obstructive CAD (HR [95% CI] = 1.91 [0.91, 4.02],
p=0.09).
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Conclusion: Patients with NSTEACS and elevated troponin but without obstructive
CAD, while having low rates of subsequent MI, are still at considerable risk for 1-year
mortality from cardiac and non-cardiac causes. Further data regarding the underlying
etiologies of death in this high-risk cohort will be presented.
TCT-388
A ‘Direct’ Transfer Protocol for Patients with Non ST-Elevation Myocardial
Infarction Reduces Time to Coronary Angiography
Sean Gallagher, Matthew Lovell, Dan Jones, Eileen Ferguson, Zia Buckhoree, Abid
Ahktar, Andrew Wragg, Andrew Archbold, Jain Ajay
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Background: Most patients with NSTEMI present to hospitals without angiography
facilities, and so wait as inpatients for transfer to the regional cardiac centre. This care
model has inherent time delays.
Methods: A novel care pathway for managing NSTEMI, known as the Heart Attack
Centre-Extension (HACX), has been investigated. This pathway identifies patients
with NSTEMI by clinical assessment and rapid troponin testing whilst in the
emergency department. Patients with NSTEMI are transferred to the regional centre
within 1 hour without referral. All unstable patients undergo immediate angiography.
Stable patients undergo angiography on the day of admission unless they arrive after
5pm; then angiography is undertaken on the next available routine list. We have
assessed need for angiography and revascularisation in 702 patients (391 before the
HACX (pre-HACX), and 311 treated via the pathway (post-HACX)). We have also
compared waiting times for angiography and length of hospital stay.
Results: 50/311 (80.4%) of HACX patients underwent angiography. 144/250 (57.6%)
were treated with coronary revascularisation (108 (75%) PCI and 36 (25%) CABG).
106/250 (42.4%) were treated with medical therapy alone. NSTE-ACS was the
discharge diagnosis for 75.4% of HACX patients. Median time from admission to
angiography was pre-HAC-X 7.2 days and post HAC-X 1.02 days (p<0.0001) (figure
1). Median length of stay was 9 days pre-HACX and 3 days post-HACX (p<0.0001).
Conclusion: This novel care pathway allows delivery of early angiography to NSTEMI
patients. The pathway allows accurate diagnosis of NSTEMI, and inappropriate
transfers are infrequent.
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Background: Previous studies suggested worse outcomes with primary PCI for
STEMI at US vs OUS sites, but there are little data in pts with NSTEACS.
Methods: ACUITY randomized 13,819 NSTEACS pts in 17 countries to an early
invasive approach with 1 of 3 strategies: 1) heparin plus GPI, 2) bivalirudin (Biv) plus
GPI, or 3) Biv alone.
Results: US pts were heavier, had more HTN, DM, prior MI, prior CABG and anemia.
OUS pts were older, had more renal insufficiency and more positive cardiac markers.
US pts were more often managed with medical therapy and less often with PCI but
had more DES use (83% vs 37%, p<0.0001). US pts received aspirin, statins and beta
blockers more often at admission, but received thienopyridines less often pre-
angiography and at discharge. At 1 yr US pts had lower mortality and lower TVR but
more MI. Bleeding was similar at 30 days. After adjusting for baseline risk, US pts
had more MI but lower TVR with no difference in mortality or MACE.
ACUITY 1 Year Outcomes: US vs OUS
Conclusion: US pts with NSTEACS had higher rates of MI but lower rates of TVR
and no differences in adjusted mortality and bleeding. Lower TVR rates may be related
to greater DES use. Higher rates of MI at US sites may be due to unmeasured
confounders, differences in the threshold for event reporting, or valid differences in
systems of care and treatment which may impact outcomes.
PCI Outcomes 
(Abstract nos 390 - 406)
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A Prospective Appropriate Use Criteria Tool Aids Revascularization Decision-
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Background: Appropriate use criteria for coronary revascularization were published
in 2009. While a large national analysis demonstrated low overall rates of inappropriate
revascularization, variability exists among institutions. We sought to determine whether
use of a prospective AUC assessment tool used at the time of procedure would improve
rates of appropriate revascularization.
Methods: A form was designed to be used at the time of diagnostic coronary
angiography. The form includes five key factors: 1) classification of angina severity,
2) level of risk based on non-invasive stress testing, 3) presence of other high risk
markers, 4) number of anti-anginal medications, and 5) coronary anatomy. The first
four to be considered prior to starting the angiogram, so that real-time decision-making
could be made about the appropriateness of revascularization once the coronary
anatomy was known.
Results: Since initiation of the AUC tool in March 2011 at our cardiac center, 216
patients underwent coronary revascularization. For these cases, overall rates of
appropriate (A), uncertain (U), and inappropriate (I) revascularization were 89%, 9%,
and 2%, respectively. Patients with acute coronary syndrome (ACS) (68%) had A, U,
and I scores of 94%, 4% and 2%, respectively. Among those with stable ischemic heart
disease (SIHD), 47% had an intermediate or high-risk noninvasive stress test. There
was infrequent use of >1 anti-anginal medication in all patients (48% in ACS versus
37% in SIHD). Compared to same facility retrospective analysis from the preceding
18 months, inappropriate rates after implementation of the AUC tool dropped from 3%
to 2%.
Conclusion: Symptoms, angina class and stress test findings predominantly drive
revascularization decisions. An unacceptably high number of patients with low risk
stress tests or suboptimal anti-anginal therapy undergo revascularization. Routine use
of our assessment tool allows the appropriateness status to be determined at the time
of procedure and results in a lower rate of inappropriate revascularization.
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